Phreesia (PHR) Projected to Post Earnings on Wednesday

Phreesia (NYSE:PHR) is expected to be posting its Q4 2026 results before the market opens on Wednesday, March 11th. Analysts expect Phreesia to post earnings of $0.10 per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Monday, March 30, 2026 at 5:00 PM ET.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, December 8th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.11. The company had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.Phreesia’s revenue for the quarter was up 12.7% on a year-over-year basis. During the same period last year, the company earned ($0.25) EPS. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Stock Performance

Shares of NYSE PHR opened at $12.07 on Tuesday. The firm’s 50-day moving average price is $14.14 and its 200-day moving average price is $19.61. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. The company has a market cap of $727.58 million, a PE ratio of -120.67 and a beta of 0.67. Phreesia has a 52-week low of $11.31 and a 52-week high of $32.76.

Insiders Place Their Bets

In other news, General Counsel Allison C. Hoffman sold 6,585 shares of Phreesia stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $112,010.85. Following the transaction, the general counsel owned 174,762 shares in the company, valued at $2,972,701.62. This trade represents a 3.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Amy Beth Vanduyn sold 2,602 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $44,260.02. Following the completion of the sale, the senior vice president owned 160,238 shares of the company’s stock, valued at $2,725,648.38. This trade represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 60,766 shares of company stock valued at $1,013,817. 5.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Phreesia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Van ECK Associates Corp lifted its holdings in Phreesia by 78.7% during the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock valued at $42,000 after purchasing an additional 1,102 shares in the last quarter. State of Wyoming purchased a new stake in shares of Phreesia in the fourth quarter worth $99,000. Tower Research Capital LLC TRC raised its position in shares of Phreesia by 332.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,610 shares of the company’s stock valued at $160,000 after purchasing an additional 4,313 shares during the period. State of Tennessee Department of Treasury purchased a new position in shares of Phreesia during the 4th quarter valued at $202,000. Finally, Creative Planning purchased a new position in shares of Phreesia during the 3rd quarter valued at $218,000. Institutional investors own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PHR. Zacks Research downgraded shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Royal Bank Of Canada assumed coverage on shares of Phreesia in a research note on Friday, January 9th. They set a “moderate buy” rating and a $26.00 target price for the company. Wells Fargo & Company started coverage on Phreesia in a report on Thursday, January 8th. They set an “overweight” rating and a $30.00 price target on the stock. Mizuho set a $22.00 price objective on Phreesia in a report on Wednesday, February 4th. Finally, Canaccord Genuity Group reduced their price objective on Phreesia from $38.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, December 9th. Seventeen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Phreesia currently has an average rating of “Moderate Buy” and an average target price of $29.12.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.